Any question about our company, a partnership, or job opportunities?
Please complete our contact form and we will get in touch ASAP
By clicking submit below, you consent to allow Gero to store and process the personal information submitted above to provide you the content requested.
Utilizing whole-exome sequencing data for in-human AI drug discovery
GERO.AI identifies rare mutations sufficiently affecting health from real-world big clinical and genetic (WES) and molecular data and then suggests druggable targets and drugs (mimicking or inhibiting) the effect of mutation to treat the disease.
We are able to aggregate the effects of multiple rare mutations on the level of biological processes and pathways and give you multiple choices of interventions with the required effect.
Longevity Biotech Gero Entered a Research Collaboration with Pfizer to Discover Potential Targets for Fibrotic Diseases
— "We are excited to work with Pfizer, one of the world’s leading biopharmaceutical companies, to potentially identify targets against fibrotic diseases, which have a large unmet need. We believe that combining our platform technology with Pfizer’s extensive disease expertise has the potential to identify high-value targets in this disease area."